Skip to main content
. Author manuscript; available in PMC: 2021 May 15.
Published in final edited form as: Clin Cancer Res. 2020 Aug 26;26(22):6017–6027. doi: 10.1158/1078-0432.CCR-20-1916

Table 2.

Associations between pharmoacokinetic (PK) parameters and changes in tumor volume, perfusion (Ktrans), angiogenic cytokines, and microvessel density.

PK Parameter Correlative Correlation* P value
Itraconazole Cmax (plasma) (ng/mL) Tumor volume Δ −0.71 0.05
Tumor MVD Δ −0.69 0.03
GM-CSF Δ −1.00 <0.001
IFN-γ Δ 1.00 <0.001
Itraconazole AUC0–4h (plasma) (ng∙mL/hr) Tumor volume Δ −0.63 0.009
Tumor MVD Δ −0.67 0.03
IL-1β Δ −0.73 0.01
IFN-γ Δ 1.00 <0.001
Hydroxyitraconazole Cave (plasma) (ng/mL) Tumor volume Δ −0.71 0.05
IL-1β Δ −0.78 0.005
IFN-γ Δ 1.00 <0.001
Itraconazole concentration (tissue) (ng/mL) Tumor volume Δ −0.59 0.04
Tumor Ktrans Δ −0.71 0.01
Tumor MVD Δ −0.69 0.06

AUC0–4h, area under the curve calculated from 0 to 4 hours; GM-CSF, granulocyte macrophage colony stimulating factor; IFN, interferon; MVD, microvessel density

*

Spearman rank correlation